Akebia Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in August 2024. The company will be present at the BTIG virtual Biotechnology Conference from August 5-6 and the Canaccord Genuity 44th Annual Growth Conference in Boston from August 13-14.

CEO John Butler will participate in a fireside chat at the BTIG conference on August 6 at 8:00 am EST. At the Canaccord Genuity conference, Mr. Butler will deliver a presentation on August 14 at 8:30 a.m. EST. Investors can access a webcast of the Canaccord Genuity presentation through Akebia's website after the conference.

News Market Reaction – AKBA

-2.78%

-2.78% Session move

In the trading session that priced this news, AKBA declined 2.78%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced participation in two investor conferences in August: BTIG virtual Biotechnology Conference, August 5-6, 2024, and Canaccord Genuity (CG) 44^th Annual Growth Conference, August 13-14, 2024 in Boston.

• BTIG Biotechnology Conference
  John Butler, Chief Executive Officer, will participate in a fireside chat on Tuesday, August 6, at 8:00 am EST.

• CG 44^th Annual Growth Conference
  Mr. Butler will present on Wednesday, August 14 at 8:30 a.m. EST. A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-upcoming-investor-conferences-302208267.html

SOURCE Akebia Therapeutics, Inc.

FAQ

What investor conferences will Akebia Therapeutics (AKBA) attend in August 2024?

Akebia Therapeutics will participate in the BTIG virtual Biotechnology Conference from August 5-6, 2024, and the Canaccord Genuity 44th Annual Growth Conference in Boston from August 13-14, 2024.

When is John Butler, CEO of Akebia Therapeutics (AKBA), scheduled to speak at the BTIG Biotechnology Conference?

John Butler is scheduled to participate in a fireside chat at the BTIG Biotechnology Conference on Tuesday, August 6, 2024, at 8:00 am EST.

What time is Akebia Therapeutics' (AKBA) presentation at the Canaccord Genuity Growth Conference?

Akebia Therapeutics' CEO John Butler will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024, at 8:30 a.m. EST.

How can investors access Akebia Therapeutics' (AKBA) presentation from the Canaccord Genuity conference?

Investors can access a webcast of Akebia Therapeutics' presentation through the 'Investors' section of the company's website at https://ir.akebia.com following the conference.